We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Medtronic announced that its Restore Rechargeable Neurostimulation System --
a device about the size of a stopwatch that is implanted under the skin -- is
now available, following approval granted by the FDA.
Molecular Devices announced the introduction of two new reagent products for
ADME (absorption, distribution, metabolism and excretion) assay screening --
Transil Membrane Affinity and Transil Human Serum Albumin (HSA) Binding assay
kits.
Siemens Medical Solutions, a wholly owned subsidiary of Siemens AG, and CTI
Molecular Imaging announced that the antitrust waiting period under the Hart-Scott-Rodino
Antitrust Improvements Act of 1976, as amended, applicable to the previously
announced tender offer to acquire all the issued and outstanding shares of CTI
Molecular Imaging has been terminated.
Ambion Diagnostics, a division of Ambion, announced that it has granted Cepheid
nonexclusive worldwide rights to incorporate Armored RNA technology in its products
and processes for in vitro molecular diagnostics.
STAAR Surgical announced that it has closed the sale of 4.1 million shares of
its common stock at $3.50 per share, for gross proceeds of $14.35 million in
a private placement to certain institutional investors.
Curon Medical announced that it has signed definitive agreements for the private
placement of common stock to institutional investors for a total of $11.3 million,
before transaction fees and expenses.
Clinical Data announced that it has entered into a worldwide distribution agreement
with Daiichi Pure Chemicals of Tokyo, Japan, for a diagnostic assay for the
measurement of an extended range of high sensitivity C-Reactive Protein (hsCRP).
Smiths Medical was awarded a three-year contract by Premier Purchasing Partners
to offer Smiths Medical TruFlow Hemodialysis Catheters to nearly 200 Premier
hospitals and healthcare systems comprised of more than 1,500 hospital facilities
in the U.S.
Mediscience Technology announced that it is in development of an adjunctive
instrument called the Cancer Detection (CD) Map, to facilitate the acquisition
of fluorescence images from surgical breast specimens (ex vivo) following lumpectomies
and surgical procedures.